New Modifier Required on all Single-Use Drugs

February 13th, 2023 - Chris Woolstenhulme
Categories:   Coding   Drugs|Pharmaceuticals|FDA   Modifiers  

Attention providers and suppliers, there is a new modifier in town! Starting July 1, 2023, Modifier JZ - Zero Drug wasted will be required on all claims to attest there is no drug leftover, If applicable. Meaning there is zero drug amount discarded, and there was no leftover drug administered to any patient.  This article will cover when the new modifier is reported and when it is not reported, how to report it on a claim, and other important information you need to know.

There is another modifier we should be familiar with, the JW modifier; this modifier has been required on claims since January 01, 2017, if applicable.  The JW modifier is required to be reported on claims if there was a drug amount that was discarded when using a single-dose container.  In addition, using the JW modifier indicates the drug is eligible for payment under the discarded drug policy. Therefore, CMS provides payment for the administered dose and the discarded amount. Using the JW modifier qualifies for separate reimbursement to providers and suppliers. 

It will be required to have one of the modifiers, JZ or JW, on a claim for a single dose, never both. Documentation requires the records to clearly document the portion of the drug administered, wasted, and leftover in the medical record.

Reasoning for the new JZ modifier
According to CMS, "Because of observed low compliance with JW modifier use (leading to incomplete JW modifier data) and because the discarded drug refund amounts rely on this data, we established that a separate modifier, the JZ modifier, will be required on claims for single-dose container drugs to attest when there are no discarded amounts no later than July 1, 2023. "

When is the JW and JZ modifier not used?
If the drug is not payable in the setting, then the modifiers are not required. For example, Rural Health Clinic (RHC) and 
Federally Qualified Health Centers (FQHC) are paid under a different payment system using a packaged rate. If a drug is packaged, it is not separately reportable as it is included in the payment. If a drug is assigned the status indicator N1, it is a "Packaged service/item; no separate payment made."

The modifiers are not required when billing vaccines; these are excluded as vaccines are often billed by mass immunizers using roster billing, which is not set up to accommodate modifiers. 

The JW modifier is only used for the amount identified on the package, never if there is an overfilled drug.

Less than the billing unit should not be reported using these modifiers; if there is anything less than a full unit, the provider reports the full unit was administered using the JZ Modifier.  

When are the Modifiers used? 
The modifiers will apply to all separately payable drugs assigned a payment indicator of K2- Drugs and biologicals paid separately when provided integral to a surgical procedure on the ASC list; payment based on OPPS rate. With the exceptions listed above, all claims reporting single-dose container drugs, including Not Otherwise Classified (NOC) codes, must be reported and documented in the patient's records.  If a drug has a status indicator of "G- pass through biologicals" or K- Non-passthrough drugs and non-implantable biologicals, including therapeutic radiopharmaceuticals." 

How are these reported on a claim?
When reporting the drug used on a claim, you will report two line items.

First line item:
One line will show the HCPCS or payment code with no modifier showing the number of units administered. 

Second line item
On a second line report, the same HCPCS code or payment code using the appropriate modifier. 

  • using the JW modifier and the number of units not used in the units field or,
  • using the JZ modifier attesting there were no discarded or leftover amounts 

Important Note: Be sure to read the complete update; this article is informational only and does not include all circumstances. 

Start reporting the new modifier now.
You can start using the new modifier anytime after the effective date of January 01, 2023, and I suggest starting now to avoid problems later, such as audits.  

CMS is implementing the JZ modifier in phases:

Providers and suppliers may report the JZ modifier as early as January 1, 2023
The JZ modifier is required on applicable claims beginning July 1, 2023

Lets Review 

After January 1, 2017, claims are subject to review if the JW modifier is used incorrectly.
After July 1, 2023, claims not reporting the JW or JZ modifier are subject to audits. 
On or after October 1, 2023, claims may be returned as unable to process.

When JW and JZ are not used
Status indicator N1
Overfilled drugs
Less than a full unit

When to report JW and JZ modifiers
Payment indicator of K2
Not Otherwise Classified (NOC) codes
Status indicator of "G" passthrough drugs
Status indicator of "K" non-passthrough drugs

Reporting on a claim
Use two line items, one for the drug code with units used and one with the drug code, the modifier attached, and applicable units.

As mentioned above, this article is informational only, and it is important to review this information released by the Medicare program.   


Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.

Latest articles:  (any category)

COVID Vaccine Coding Changes as of November 1, 2023
October 26th, 2023 - Wyn Staheli
COVID vaccine changes due to the end of the PHE as of November 1, 2023 are addressed in this article.
Medicare Guidance Changes for E/M Services
October 11th, 2023 - Wyn Staheli
2023 brought quite a few changes to Evaluation and management (E/M) services. The significant revisions as noted in the CPT codebook were welcome changes to bring other E/M services more in line with the changes that took place with Office or Other Outpatient Services a few years ago. As part of CMS’ Medicare Learning Network, the “Evaluation and Management Services Guide” publication was finally updated as of August 2023 to include the changes that took place in 2023. If you take a look at the new publication (see references below),....
Can We Score Interpretation of an EKG Towards E/M Medical Decision Making?
October 10th, 2023 - Aimee Wilcox
When EKGs are performed in the facility setting or even in the physician's office, what are the requirements for reporting the service and who gets credit for scoring data points for Evaluation and Management (E/M) medical decision making (MDM)? Let's take a look at a few coding scenarios related to EKG services to get a better understanding of why this can be problematic.
Accurately Reporting Signs and Symptoms with ICD-10-CM Codes
October 5th, 2023 - Aimee Wilcox
Coders often find themselves unsure of when to report a sign or symptom code documented in the medical record. Some coders find their organization has an EHR that requires a working diagnosis, which is usually a sign or symptom, be entered to order a test or diagnostic study or image. Understanding the guidelines surrounding when signs and symptoms should be reported is the first step in correct coding so let's take a look at some scenarios.
The 2024 ICD-10-CM Updates Include New Codes for Reporting Metabolic Disorders and Insulin Resistance
September 19th, 2023 - Aimee Wilcox
Diabetes is a chronic disease that just seems to consistently be increasing instead of improving resulting in a constant endeavor by medical researchers to identify causal effects and possible treatments. One underlying or precipitating condition that scientists have identified as a precipitating factor in the development of diabetes is insulin resistance, which is a known metabolic disorder. As data becomes available through claims reporting, additional code options become possible with ICD-10-CM.
Documenting and Reporting Postoperative Visits
September 12th, 2023 - Aimee Wilcox
Sometimes we receive questions regarding documentation requirements for specific codes or coding requirements and we respond with information and resources to support our answers. The following question was recently submitted: Are providers required to report postoperative services on claims using 99024, especially if there is no payment for that service? What documentation is required if you are reporting an unrelated Evaluation and Management (E/M) service by the same physician during the postoperative period? 
Understanding Gastroesophageal Reflux Disease and ICD-10-CM Coding
August 22nd, 2023 - Aimee Wilcox
Gastroesophageal reflux disease or GERD for short, is a disease that impacts millions of Americans on a weekly basis. Symptoms are uncomfortable, as are some of the tests used to diagnose it, but understanding the disease, tests, and treatments helps us better understand how to code the disease using ICD-10-CM codes.

Home About Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2023 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association